Skip to main content
. 2017 Apr 26;2017(4):CD010770. doi: 10.1002/14651858.CD010770.pub2

NCT01069094.

Methods Randomised controlled trial
Participants Premenopausal women with fibroids
Interventions Telapristone acetate (12.5 mg, 25 mg and 50 mg) vs Lupron depot vs placebo
Outcomes Assess the safety of Progenta when administered in premenopausal women with symptomatic leiomyomata
Notes Protocol NCT01069094 in clinicaltrials.gov of telapristone acetate vs Lupron depot vs placebo. No results in database nor in published literature. States trial was completed